351 related articles for article (PubMed ID: 32079690)
1. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.
Autio M; Leivonen SK; Brück O; Mustjoki S; Mészáros Jørgensen J; Karjalainen-Lindsberg ML; Beiske K; Holte H; Pellinen T; Leppä S
Haematologica; 2021 Mar; 106(3):718-729. PubMed ID: 32079690
[TBL] [Abstract][Full Text] [Related]
2. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
Leivonen SK; Pollari M; Brück O; Pellinen T; Autio M; Karjalainen-Lindsberg ML; Mannisto S; Kellokumpu-Lehtinen PL; Kallioniemi O; Mustjoki S; Leppä S
Haematologica; 2019 Feb; 104(2):338-346. PubMed ID: 30237271
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
4. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma.
Pollari M; Pellinen T; Karjalainen-Lindsberg ML; Kellokumpu-Lehtinen PL; Leivonen SK; Leppä S
Eur J Haematol; 2020 Dec; 105(6):712-721. PubMed ID: 32632935
[TBL] [Abstract][Full Text] [Related]
5. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma.
Song JY; Nwangwu M; He TF; Zhang W; Meawad H; Bedell V; Murata-Collins J; Skrabek P; Nasr MR; Scott D; Godfrey J; Lee P; Chan WC; Weisenburger DD; Perry AM; Herrera AF
Haematologica; 2023 Aug; 108(8):2167-2177. PubMed ID: 36632739
[TBL] [Abstract][Full Text] [Related]
6. OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma.
Lu Y; Li Y; Yu J; Meng S; Bi C; Guan Q; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Armitage J; Zhang H; Fu K; Wang X
Clin Immunol; 2023 Jun; 251():109637. PubMed ID: 37150239
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell lymphoma: the significance of CD8
Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S
J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502
[TBL] [Abstract][Full Text] [Related]
8. Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma.
Lee CW; Ren YJ; Marella M; Wang M; Hartke J; Couto SS
J Immunol Methods; 2020 Mar; 478():112714. PubMed ID: 31783023
[TBL] [Abstract][Full Text] [Related]
9. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
10. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
11. A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma.
Lee H; Yoon SE; Kim SJ; Kim WS; Cho J
Cancer Med; 2023 Aug; 12(15):16359-16369. PubMed ID: 37326144
[TBL] [Abstract][Full Text] [Related]
12. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.
Roussel M; Le KS; Granier C; Llamas Gutierrez F; Foucher E; Le Gallou S; Pangault C; Xerri L; Launay V; Lamy T; Tartour E; Olive D; Fest T
Blood Adv; 2021 Apr; 5(7):1816-1829. PubMed ID: 33787861
[TBL] [Abstract][Full Text] [Related]
14. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.
Keane C; Law SC; Gould C; Birch S; Sabdia MB; Merida de Long L; Thillaiyampalam G; Abro E; Tobin JW; Tan X; Xu-Monette ZY; Young KH; Gifford G; Gabreilli S; Stevenson WS; Gill A; Talaulikar D; Jain S; Hernandez A; Halliday SJ; Bird R; Cross D; Hertzberg M; Gandhi MK
Blood Adv; 2020 Apr; 4(7):1367-1377. PubMed ID: 32267932
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
16. Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.
Carreras J; Yukie Kikuti Y; Miyaoka M; Hiraiwa S; Tomita S; Ikoma H; Kondo Y; Shiraiwa S; Ando K; Sato S; Suzuki Y; Miura I; Roncador G; Nakamura N
Am J Surg Pathol; 2018 Jul; 42(7):936-950. PubMed ID: 29738359
[TBL] [Abstract][Full Text] [Related]
17. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
[TBL] [Abstract][Full Text] [Related]
18. Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival.
Chao C; Xu L; Silverberg MJ; Martínez-Maza O; Chen LH; Castor B; Abrams DI; Zha HD; Haque R; Said J
AIDS; 2015 Sep; 29(15):1943-51. PubMed ID: 26355571
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
[TBL] [Abstract][Full Text] [Related]
20. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
